Regulation of Cdk5 activity during inflammation: In light of our earlier findings on the important role of Cdk5 in inflammation-induced pain, we continued our studies further to identify which molecules released during inflammation induce Cdk5 activity. Using a PC12 cell-based assay developed in our laboratory, we first screened known pro-inflammatory chemokines, leukotrienes and cytokines for their effects on Cdk5 kinase activity. Through these studies, we identified that tumor necrosis factor-alpha (TNF-alpha) induces a sustained and robust expression of p35, a coactivator of Cdk5, thereby increasing Cdk5 kinase activity. The activation of ERK1/2 by TNF-alpha leads to an increase in Egr-1 expression and the subsequent elevation of p35 expression. Furthermore, we demonstrated that the experimental inflammation induced by injecting carrageenan in mouse paw increases expression of TNF-alpha which in turn induces more Cdk5 activity, resulting in elevated pain signaling. Phosphoproteomic analysis of Cdk5 targets: The human genome encodes over 500 different protein kinases, which are the key regulatory enzymes that catalyze the phosphorylation of proteins at about 100,000 different sites to reversibly control their functional activities. Defects in specific protein kinases have been linked to over 400 diseases, and about 25% of all pharmaceutical industry research and development is now focused on the discovery and evaluation of protein kinase inhibitors for therapeutic applications. Cdk5 has become a target of high interest to the drug industry because of its key role in neuronal homeostasis. So far more than 40 different Cdk5 substrates have been identified, and abnormal Cdk5 activity has been implicated in several disease processes, including neurodegenerative disorders, cancer, and diabetes. However, a global profiling of protein phosphorylation mediated by Cdk5 is still not available. Our current knowledge about such profiling comes from experiments that are performed in different laboratories and are mainly based on 2-dimensional gel electrophoresis or yeast 2-hybrid screening. Because of the limitations of these techniques at the point of validation of targeted proteins, we took a different approach to resolve this issue. We compared the phosphorylation status and the total protein levels of 258 different proteins through simple Western blotting analysis of Cdk5-/- and WT wild-type brains. The antibodies used in this analysis had already proven to be highly specific for their targeted sites in different biochemical pathways. We based our selection of these proteins on some known and predicted functions of Cdk5, and further categorized them into the following groups: apoptosis, kinases, cell cycle, and neurodegeneration. We have now validated some of these proteins by further testing, and we will continue to study them for their cellular roles. It is clear now that Cdk5 plays an important role in many neuronal functions and especially in pain signaling. The overall strategy for our future work is focused on delineating the molecular roles of Cdk5 in pain signaling, with an emphasis on the facial and oral region.

Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2010
Total Cost
$696,702
Indirect Cost
Name
National Institute of Dental & Craniofacial Research
Department
Type
DUNS #
City
State
Country
Zip Code
Wankhade, Umesh D; Lee, Ji-Hyeon; Dagur, Pradeep K et al. (2018) TGF-? receptor 1 regulates progenitors that promote browning of white fat. Mol Metab 16:160-171
Hall, Bradford E; Prochazkova, Michaela; Sapio, Matthew R et al. (2018) Phosphorylation of the Transient Receptor Potential Ankyrin 1 by Cyclin-dependent Kinase 5 affects Chemo-nociception. Sci Rep 8:1177
Prochazkova, Michaela; Hall, Bradford; Hu, Minghan et al. (2017) Peripheral and orofacial pain sensation is unaffected by the loss of p39. Mol Pain 13:1744806917737205
Coddou, Claudio; Sandoval, Rodrigo; Castro, Patricio et al. (2017) Cyclin-dependent kinase 5 modulates the P2X2a receptor channel gating through phosphorylation of C-terminal threonine 372. Pain 158:2155-2168
Bu, L L; Yu, G T; Wu, L et al. (2017) STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. J Dent Res 96:1027-1034
Mao, Liang; Fan, Teng-Fei; Wu, Lei et al. (2017) Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. J Cell Mol Med 21:2199-2210
Ma, Si-Rui; Deng, Wei-Wei; Liu, Jian-Feng et al. (2017) Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer 16:99
Liu, Jian-Feng; Ma, Si-Rui; Mao, Liang et al. (2017) T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. Mol Oncol 11:235-247
Mao, Liang; Deng, Wei-Wei; Yu, Guang-Tao et al. (2017) Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer. Int J Cancer 140:1173-1185
Meijer, Laurent; Nelson, Deborah J; Riazanski, Vladimir et al. (2016) Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. J Innate Immun 8:330-49

Showing the most recent 10 out of 52 publications